1. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Issue 5 (May 2018) Authors: Dummer, Reinhard; Ascierto, Paolo A; Gogas, Helen J; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; Chiarion-Sileni, Vanna; Dutriaux, Caroline; de Groot, Jan Willem B; Yamazaki, Naoya; Loquai, Carmen; Moutouh-de Parseval, Laure A;... Journal: Lancet oncology Issue: Volume 19:Issue 5(2018) Page Start: 603 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Issue 7 (July 2018) Authors: Dreno, Brigitte; Thompson, John F; Smithers, Bernard Mark; Santinami, Mario; Jouary, Thomas; Gutzmer, Ralf; Levchenko, Evgeny; Rutkowski, Piotr; Grob, Jean-Jacques; Korovin, Sergii; Drucis, Kamil; Grange, Florent; Machet, Laurent; Hersey, Peter; Krajsova, Ivana; Testori, Alessandro; Conry, Robert... Journal: Lancet oncology Issue: Volume 19:Issue 7(2018) Page Start: 916 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. (July 2017) Authors: Blank, Christian U.; Larkin, James; Arance, Ana M.; Hauschild, Axel; Queirolo, Paola; Del Vecchio, Michele; Ascierto, Paolo A.; Krajsova, Ivana; Schachter, Jacob; Neyns, Bart; Garbe, Claus; Chiarion Sileni, Vanna; Mandalà, Mario; Gogas, Helen; Espinosa, Enrique; Hospers, Geke A.P.; Miller, Wilson... Journal: European journal of cancer Issue: Volume 79(2017) Page Start: 176 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Issue 10 (October 2018) Authors: Dummer, Reinhard; Ascierto, Paolo A; Gogas, Helen J; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; Chiarion Sileni, Vanna; Dutriaux, Caroline; de Groot, Jan Willem B; Yamazaki, Naoya; Loquai, Carmen; Moutouh-de Parseval, Laure A;... Journal: Lancet oncology Issue: Volume 19:Issue 10(2018) Page Start: 1315 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma. (February 2020) Authors: Ascierto, Paolo A.; Dummer, Reinhard; Gogas, Helen J.; Flaherty, Keith T.; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; de Groot, Jan Willem B.; Loquai, Carmen; Gollerkeri, Ashwin; Pickard, Michael D.; Robert, Caroline Journal: European journal of cancer Issue: Volume 126(2020) Page Start: 33 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗